Continue to site >
Trending ETFs

Name

As of 05/17/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$10.85

$104 M

0.00%

0.50%

Vitals

YTD Return

-6.1%

1 yr return

-14.8%

3 Yr Avg Return

-19.2%

5 Yr Avg Return

-4.7%

Net Assets

$104 M

Holdings in Top 10

45.1%

52 WEEK LOW AND HIGH

$10.9
$8.77
$13.05

Expenses

OPERATING FEES

Expense Ratio 0.50%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 05/17/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$10.85

$104 M

0.00%

0.50%

GNOM - Profile

Distributions

  • YTD Total Return -6.1%
  • 3 Yr Annualized Total Return -19.2%
  • 5 Yr Annualized Total Return -4.7%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.35%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency SemiAnnual

Fund Details

  • Legal Name
    Global X Genomics & Biotechnology ETF
  • Fund Family Name
    Global X Funds
  • Inception Date
    Apr 05, 2019
  • Shares Outstanding
    14292596
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Nam To

Fund Description

The Fund invests at least 80% of its total assets in the securities of the Solactive Genomics Index ("Underlying Index"). The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Fund’s total assets (including the value of the collateral received).
The Underlying Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the Underlying Index ("Index Provider"). In order to be eligible for inclusion in the Underlying Index, a company is considered by the Index Provider to be a Genomics & Biotechnology Company if it derives at least 50% of its revenue, operating income, or assets from genomics and/or biotechnology. These companies include those involved in the following business activities: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.
In constructing the Underlying Index, the Index Provider first establishes the eligible universe by utilizing FactSet sector classifications: only companies classified by FactSet as healthcare companies are eligible for the Underlying Index. The Index Provider then applies a proprietary natural language processing algorithm to the eligible universe, which seeks to identify and rank companies with direct exposure to the genomics industry based on filings, disclosures and other public information (e.g.
regulatory filings, earnings transcripts, etc.). The highest ranking companies identified by the natural language processing algorithm, as of the selection date, are further reviewed by the Index Provider to confirm they derive at least 50% of their revenues, operating income, or assets from the following business activities:
i.Gene Editing: Companies that develop technology for the insertion, deletion, or replacement of DNA at a specific site in the genome of an organism.
ii.Genomic Sequencing: Companies that are engaged in the process of determining the complete DNA sequence of an organism's genome.
iii.Genetic Medicine/Therapies: Companies that seek to detect, cure or treat diseases by identifying and/or modifying an organism's gene expression or functioning.
iv.Computational Genomics and Genetic Diagnostics: Companies that use computational and statistical analysis to decipher biological insights from genome sequences and related data.
v.Biotechnology: Companies that combine biologic processes and technology to develop products and services.
The eligible universe of the Underlying Index includes exchange-listed companies that meet minimum market capitalization and liquidity criteria, as defined by the Index Provider. As of January 31, 2024, companies must have a minimum market capitalization of $200 million and a minimum average daily turnover for the last 6 months greater than or equal to $2 million in order to be eligible for inclusion in the Underlying Index. As of January 31, 2024, companies listed in the following countries were eligible for inclusion in the Underlying Index: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, the United Kingdom, and the United States. Additionally, ADRs of any company whose primary listing is in a country that is part of the Emerging markets are eligible.
The Underlying Index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually. Modified capitalization weighting seeks to weight constituents primarily based on market capitalization, but subject to caps on the weights of the individual securities. Generally speaking, this approach will limit the amount of concentration in the largest market capitalization companies and increase company-level diversification. The Underlying Index may include large-, mid- or small-capitalization companies, and components primarily include healthcare companies. As of January 31, 2024, the Underlying Index had 40 constituents. The Fund's investment objective and Underlying Index may be changed without shareholder approval.
The Underlying Index is sponsored by the Index Provider, which is an organization that is independent of, and unaffiliated with, the Fund and Global X Management Company LLC, the investment adviser for the Fund ("Adviser"). The Index Provider determines the relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
The Adviser uses a "passive" or indexing approach to try to achieve the Fund's investment objective. Unlike many investment companies, the Fund does not try to outperform the Underlying Index and does not seek temporary defensive positions when markets decline or appear overvalued.
The Fund generally will use a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Underlying Index in approximately the same proportions as in the Underlying Index. However, the Fund may utilize a representative sampling strategy with respect to the Underlying Index when a replication strategy might be detrimental or disadvantageous to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index, in instances in which a security in the Underlying Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Underlying Index.
The Adviser expects that, over time, the correlation between the Fund's performance and that of the Underlying Index, before fees and expenses, will exceed 95%. A correlation percentage of 100% would indicate perfect correlation.
The Fund concentrates its investments (i.e., holds 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. As of January 31, 2024, the Underlying Index was concentrated in the biotechnology and life sciences tools & services industries and had significant exposure to the health care sector.
Read More

GNOM - Performance

Return Ranking - Trailing

Period GNOM Return Category Return Low Category Return High Rank in Category (%)
YTD -6.1% -19.1% 20.3% 98.15%
1 Yr -14.8% -17.0% 25.9% 99.38%
3 Yr -19.2%* -30.0% 13.2% 99.35%
5 Yr -4.7%* -4.7% 16.0% 100.00%
10 Yr N/A* 0.4% 13.9% 73.95%

* Annualized

Return Ranking - Calendar

Period GNOM Return Category Return Low Category Return High Rank in Category (%)
2023 -8.6% -12.6% 19.0% 97.53%
2022 -36.3% -53.9% 3.2% 96.13%
2021 -16.0% -39.6% 24.2% 78.71%
2020 51.3% -13.6% 178.2% 4.64%
2019 N/A 3.8% 63.8% N/A

Total Return Ranking - Trailing

Period GNOM Return Category Return Low Category Return High Rank in Category (%)
YTD -6.1% -19.1% 20.3% 98.15%
1 Yr -14.8% -17.0% 25.9% 99.38%
3 Yr -19.2%* -30.0% 13.2% 99.35%
5 Yr -4.7%* -4.7% 16.0% 100.00%
10 Yr N/A* 0.4% 13.9% N/A

* Annualized

Total Return Ranking - Calendar

Period GNOM Return Category Return Low Category Return High Rank in Category (%)
2023 -8.6% -12.6% 19.0% 97.53%
2022 -36.3% -53.9% 3.7% 96.13%
2021 -15.9% -33.9% 26.0% 90.97%
2020 51.5% -0.7% 180.6% 6.62%
2019 N/A 4.6% 63.8% N/A

GNOM - Holdings

Concentration Analysis

GNOM Category Low Category High GNOM % Rank
Net Assets 104 M 7.41 M 47.2 B 78.40%
Number of Holdings 41 23 420 88.89%
Net Assets in Top 10 44.5 M 2.19 M 20.5 B 77.78%
Weighting of Top 10 45.08% 18.1% 77.0% 54.32%

Top 10 Holdings

  1. NATERA INC COMMON STOCK 6.47%
  2. CRISPR THERAPEUTICS AG COMMON STOCK 6.44%
  3. ULTRAGENYX PHARMACEUTICAL IN COMMON STOCK 4.72%
  4. BEAM THERAPEUTICS INC COMMON STOCK 4.42%
  5. ARROWHEAD PHARMACEUTICALS IN COMMON STOCK 4.01%
  6. AGILENT TECHNOLOGIES INC COMMON STOCK 3.98%
  7. INTELLIA THERAPEUTICS INC COMMON STOCK 3.95%
  8. 10X GENOMICS INC-CLASS A COMMON STOCK 3.77%
  9. ILLUMINA INC COMMON STOCK 3.68%
  10. ROCKET PHARMACEUTICALS INC COMMON STOCK 3.66%

Asset Allocation

Weighting Return Low Return High GNOM % Rank
Stocks
99.97% 87.17% 106.13% 6.79%
Cash
0.03% 0.00% 34.44% 95.06%
Preferred Stocks
0.00% 0.00% 7.86% 68.52%
Other
0.00% -22.99% 23.31% 74.07%
Convertible Bonds
0.00% 0.00% 0.37% 58.60%
Bonds
0.00% 0.00% 12.39% 61.73%

Stock Sector Breakdown

Weighting Return Low Return High GNOM % Rank
Healthcare
100.00% 59.26% 100.00% 29.94%
Utilities
0.00% 0.00% 0.00% 55.41%
Technology
0.00% 0.00% 22.69% 59.24%
Real Estate
0.00% 0.00% 5.89% 57.96%
Industrials
0.00% 0.00% 7.02% 59.24%
Financial Services
0.00% 0.00% 1.60% 70.70%
Energy
0.00% 0.00% 0.00% 55.41%
Communication Services
0.00% 0.00% 9.11% 57.96%
Consumer Defense
0.00% 0.00% 25.73% 59.87%
Consumer Cyclical
0.00% 0.00% 1.92% 57.96%
Basic Materials
0.00% 0.00% 7.16% 70.06%

Stock Geographic Breakdown

Weighting Return Low Return High GNOM % Rank
US
97.06% 66.21% 104.41% 28.40%
Non US
2.91% 0.00% 28.58% 45.68%

GNOM - Expenses

Operational Fees

GNOM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.50% 0.08% 4.28% 85.80%
Management Fee 0.50% 0.03% 1.25% 16.05%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

GNOM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

GNOM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

GNOM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 0.00% 238.00% N/A

GNOM - Distributions

Dividend Yield Analysis

GNOM Category Low Category High GNOM % Rank
Dividend Yield 0.00% 0.00% 6.24% 73.46%

Dividend Distribution Analysis

GNOM Category Low Category High Category Mod
Dividend Distribution Frequency SemiAnnual Annual Annual Annual

Net Income Ratio Analysis

GNOM Category Low Category High GNOM % Rank
Net Income Ratio -0.35% -2.54% 1.85% 60.00%

Capital Gain Distribution Analysis

GNOM Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

GNOM - Fund Manager Analysis

Managers

Nam To


Start Date

Tenure

Tenure Rank

Apr 05, 2019

3.16

3.2%

Nam To, CFA, joined Global X Management Company LLC in July 2017 as a Portfolio Management Analyst. Mr. To has been a Portfolio Manager of the Fund since March 1, 2018. Previously, Mr. To was a Global Economics Research Analyst at Bunge Limited from 2014 through 2017 and an Advisory and Investment Analyst at Horizon Capital Group from June 2013 through August 2013. Mr. To received his Bachelor of Arts in Philosophy and Economics from Cornell University in 2014.

Wayne Xie


Start Date

Tenure

Tenure Rank

Apr 05, 2019

3.16

3.2%

Wayne Xie joined the Global X Management Company LLC in July 2018 as a Portfolio Management Associate. Previously, Mr. Xie was an Analyst at VanEck Associates on the Equity ETF Investment Management team from 2010 to 2018 and a Portfolio Administrator at VanEck Associates from 2007 to 2010. Mr. Xie received his BS in Business Administration from State University of New York at Buffalo.

Kimberly Chan


Start Date

Tenure

Tenure Rank

Jun 10, 2019

2.98

3.0%

Kimberly Chan is a Portfolio Management Associate. Previously, Ms. Chan was a US Associate Trader at Credit Agricole from 2016 to 2018, and an Investment Analyst at MetLife Investments from 2015 to 2016. Ms. Chan received her Bachelor of Science from New York University in 2015.

Vanessa Yang


Start Date

Tenure

Tenure Rank

Dec 31, 2020

1.41

1.4%

Vanessa Yang, Portfolio Management Associate, joined Global X Management Company LLC in 2016 as a Portfolio Administrator. She was appointed to the portfolio management team in June 2019. Previously, Ms. Yang was a Portfolio Administrator at VanEck Associates from 2011 to 2014. Ms. Yang received her MS in Financial Engineering from Drucker School of Management in 2010 and her BS in Economics from Guangdong University of Foreign Studies in 2008.

Sandy Lu


Start Date

Tenure

Tenure Rank

Apr 01, 2022

0.16

0.2%

Sandy Lu, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Lu worked at PGIM Fixed Income from 2014 to 2021, where he led the portfolio analyst team covering Emerging Markets Debt. He began his career in 2010 as an Investment Analyst at Lincoln Financial Group. Mr. Lu graduated with a B.S. in Economics from the Wharton School of the University of Pennsylvania. He earned his CFA designation in September 2015, and holds the Series 3 license.

William Helm


Start Date

Tenure

Tenure Rank

Apr 01, 2022

0.16

0.2%

William Helm, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Helm spent 14 years at Vanguard where he most recently served as an Equity Portfolio Manager and Trader. Previously, he held roles in Portfolio Review, Corporate Strategy and Corporate Finance. Mr. Helm received his BBA in Economics from Belmont University in 2007 and his MBA from Columbia Business School in 2020.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25